These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone. Laplante Y; Cadot C; Fournier MA; Poirier D Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543 [TBL] [Abstract][Full Text] [Related]
3. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. Pasqualini JR; Chetrite GS J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265 [TBL] [Abstract][Full Text] [Related]
4. Steroidal affinity labels of the estrogen receptor. 3. Estradiol 11 beta-n-alkyl derivatives bearing a terminal electrophilic group: antiestrogenic and cytotoxic properties. Lobaccaro C; Pons JF; Duchesne MJ; Auzou G; Pons M; Nique F; Teutsch G; Borgna JL J Med Chem; 1997 Jul; 40(14):2217-27. PubMed ID: 9216841 [TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity. Murphy CS; Parker CJ; McCague R; Jordan VC Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of estrone sulfate-induced uterine growth by potent nonestrogenic steroidal inhibitors of steroid sulfatase. Ciobanu LC; Luu-The V; Martel C; Labrie F; Poirier D Cancer Res; 2003 Oct; 63(19):6442-6. PubMed ID: 14559834 [TBL] [Abstract][Full Text] [Related]
7. Assessment of estrogenic activity in some common essential oil constituents. Howes MJ; Houghton PJ; Barlow DJ; Pocock VJ; Milligan SR J Pharm Pharmacol; 2002 Nov; 54(11):1521-8. PubMed ID: 12495555 [TBL] [Abstract][Full Text] [Related]
8. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314 [TBL] [Abstract][Full Text] [Related]
9. Progestins and breast cancer. Pasqualini JR Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():32-41. PubMed ID: 17943537 [TBL] [Abstract][Full Text] [Related]
10. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Osborne CK; Hobbs K; Clark GM Cancer Res; 1985 Feb; 45(2):584-90. PubMed ID: 3967234 [TBL] [Abstract][Full Text] [Related]
11. Hydroxylated polychlorinated biphenyls (PCBs) as estrogens and antiestrogens: structure-activity relationships. Connor K; Ramamoorthy K; Moore M; Mustain M; Chen I; Safe S; Zacharewski T; Gillesby B; Joyeux A; Balaguer P Toxicol Appl Pharmacol; 1997 Jul; 145(1):111-23. PubMed ID: 9221830 [TBL] [Abstract][Full Text] [Related]
13. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells. Shields-Botella J; Chetrite G; Meschi S; Pasqualini JR J Steroid Biochem Mol Biol; 2005 Jan; 93(1):1-13. PubMed ID: 15748827 [TBL] [Abstract][Full Text] [Related]
14. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645 [TBL] [Abstract][Full Text] [Related]
15. Effect of halogenated substituents on the metabolism and estrogenic effects of the equine estrogen, equilenin. Liu X; Zhang F; Liu H; Burdette JE; Li Y; Overk CR; Pisha E; Yao J; van Breemen RB; Swanson SM; Bolton JL Chem Res Toxicol; 2003 Jun; 16(6):741-9. PubMed ID: 12807357 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of B-, C-, and D-ring-substituted estradiol carboxylic acid esters as locally active estrogens. Labaree DC; Zhang JX; Harris HA; O'Connor C; Reynolds TY; Hochberg RB J Med Chem; 2003 May; 46(10):1886-904. PubMed ID: 12723952 [TBL] [Abstract][Full Text] [Related]
17. Modulation of estrogen action during preimplantation period and in immature estradiol-primed rat uterus by anti-implantation agent, ormeloxifene. Dwivedi A; Basu R; Chowdhury SR; Goyal N Contraception; 2005 Jun; 71(6):458-64. PubMed ID: 15914137 [TBL] [Abstract][Full Text] [Related]
18. Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation. Tremblay MR; Poirier D J Steroid Biochem Mol Biol; 1998 Aug; 66(4):179-91. PubMed ID: 9744515 [TBL] [Abstract][Full Text] [Related]
19. Estrogen-stimulated prolactin synthesis in vitro. Classification of agonist, partial agonist, and antagonist actions based on structure. Jordan VC; Lieberman ME Mol Pharmacol; 1984 Sep; 26(2):279-85. PubMed ID: 6541293 [TBL] [Abstract][Full Text] [Related]
20. Antiestrogen pharmacology and mechanism of action. Katzenellenbogen BS; Miller MA; Eckert RL; Sudo K J Steroid Biochem; 1983 Jul; 19(1A):59-68. PubMed ID: 6887873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]